CBIO GLYCOMIMETICS INC

Nasdaq glycomimetics.com


$ 13.02 $ 0.54 (4.34 %)    

Thursday, 06-Nov-2025 15:56:26 EST
QQQ $ 611.79 $ -10.00 (-1.61 %)
DIA $ 469.36 $ -2.67 (-0.57 %)
SPY $ 670.46 $ -6.01 (-0.89 %)
TLT $ 89.76 $ 0.20 (0.22 %)
GLD $ 366.16 $ -1.04 (-0.28 %)
$ 12.43
$ 12.44
$ 13.02 x 9
$ 13.14 x 100
$ 12.69 - $ 13.10
$ 9.81 - $ 44.77
44,476
na
172.68M
$ 1.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 02-13-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 03-29-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 04-28-2022 03-31-2022 10-Q
16 03-03-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-03-2021 03-31-2021 10-Q
20 03-02-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-01-2020 03-31-2020 10-Q
24 02-28-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 03-06-2019 12-31-2018 10-K
29 11-02-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 03-06-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-08-2017 03-31-2017 10-Q
36 03-01-2017 12-31-2016 10-K
37 11-04-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-04-2016 03-31-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 crescent-biopharma-q3-eps-127-beats-198-estimate

Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(...

 crescent-biopharma-to-present-preclinical-data-from-cr-001-antibody-for-solid-tumor-tumors-at-society-for-immunotherapy-of-cancer

Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a biotechnology company dedicated to rap...

 hc-wainwright--co-reiterates-buy-on-crescent-biopharma-maintains-25-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $25 ...

 jefferies-initiates-coverage-on-crescent-biopharma-with-buy-rating-announces-price-target-of-26

Jefferies analyst Akash Tewari initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price ...

 hc-wainwright--co-initiates-coverage-on-crescent-biopharma-with-buy-rating-announces-price-target-of-25

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating ...

 wedbush-initiates-coverage-on-crescent-biopharma-with-outperform-rating-announces-price-target-of-27

Wedbush analyst Robert Driscoll initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and announce...

 stifel-initiates-coverage-on-crescent-biopharma-with-buy-rating-announces-price-target-of-28

Stifel analyst Stephen Willey initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price T...

 lifesci-capital-initiates-coverage-on-crescent-biopharma-with-outperform-rating-announces-price-target-of-22

LifeSci Capital analyst Charles Zhu initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and anno...

 us-stocks-likely-to-open-higher-despite-trumps-unconditional-surrender-call-all-eyes-on-powell-as-experts-predict-inflation-will-limit-feds-rate-cut-capacity

U.S. futures were higher on Wednesday as oil futures tumbled after Donald Trump called for an "Unconditional Surrender"...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION